501(c)(3) Public Charity  ·  Indianapolis, Indiana

The cure for kidney disease
is waiting in the lab.
Help us get it out.

37 million Americans live with chronic kidney disease. The science to treat it exists. What it needs is funding, belief, and people who refuse to accept the status quo. That's where you come in.

Scroll
The Problem

A crisis hiding in plain sight

37M
Americans living with chronic kidney disease
$114B
Annual US cost of CKD & related heart failure
0
FDA-approved drugs targeting the apelin pathway

CKD disproportionately strikes low-income communities and communities of color. It is chronically underfunded — receiving roughly $20 per patient in federal research dollars, compared to $2,000 per patient for HIV.

The Heroes in the Lab

Dr. Kenneth Lim built the only lab of its kind in America.
Your gift keeps it running.

Most researchers study kidney disease with the tools of the last generation. Dr. Lim's lab at Indiana University School of Medicine is doing something different — and donors make it possible.

Inside the Division of Nephrology & Hypertension at IUSM, Dr. Lim leads a research group unlike any other in the country. He founded the first and only cardiopulmonary exercise testing (CPET) laboratory in the United States dedicated entirely to patients with kidney disease — a platform so novel it's opening a completely new window into how CKD destroys the cardiovascular system.

His wet lab runs parallel to the clinical work — developing peptide therapeutics like AP001 through 11 iterations of analog design, bringing a molecule closer each year to its first human trial. This is the kind of long, painstaking translational science that transforms a mechanism understood in biology into a medicine a patient can actually take.

The metabolic disease epidemic — obesity, type 2 diabetes, and the cardiovascular collapse that follows — is the landscape in which CKD lives. Dr. Lim's team studies the whole picture: the cardiorenal syndrome, the mechanisms linking kidney failure to heart failure, and the novel drugs that might interrupt that cycle for the first time.

Donors fund this work directly. Every grant we award to Dr. Lim's lab buys more time on the CPET machine, another iteration of AP001, another year of the ROCK-D study enrolling hemodialysis patients. This is your lab as much as his.

🔬
CPET Laboratory — First in the US for Kidney DiseaseState-of-the-art cardiopulmonary exercise testing with breath-by-breath metabolic analysis, non-invasive cardiac output monitoring, 12-lead EKG, and real-time cardiovascular tracking during exercise.
💊
AP001 — 11 Iterations and CountingA proprietary analog of apelin-13, engineered to extend half-life for clinical use. The first molecule designed to protect heart and kidneys simultaneously. No approved drug does this.
📊
ROCK-D & FIT-INDY — NIH-Funded Clinical StudiesROCK-D enrolls 140 hemodialysis patients for comprehensive cardiovascular assessment using CPET, cardiac MRI, and coronary artery CT. FIT-INDY examines cardiorespiratory fitness across CKD stages. Both actively enrolling in 2025.
🔄
Translational by DesignBench discoveries inform trial design. Clinical observations shape the next molecule. Most labs never close that loop — it's what makes AP001 more than a hypothesis.
KL
Dr. Kenneth Lim
MD · PhD · MPhil · FASN · FAHA · FRCP

Tenure-Track Assistant Professor of Medicine at Indiana University School of Medicine. Attending Physician at IU Health. Before joining IU in 2020, Dr. Lim spent over a decade at Harvard Medical School and Massachusetts General Hospital.

  • University of Cambridge (Christ's College) & University of Warwick
  • 10+ years at Harvard Medical School & Mass General Hospital
  • Fellow, American Heart Association (FAHA)
  • Fellow, American Society of Nephrology (FASN)
  • Fellow, Royal College of Physicians (FRCP)
  • Principal Investigator, NIH NHLBI R01
  • Founder — first CPET lab for kidney disease in the US
  • Scientific Advisory Board, MBX Biosciences
  • Member, American Society for Clinical Investigation
AP001 — The Discovery

A naturally occurring mechanism that protects heart and kidneys at once. No drug has ever targeted it. Until now.

01
The Apelin Pathway
Apelin-13 activates the APJ receptor, expressed in both cardiac and renal tissue. When activated it lowers blood pressure, improves heart contractility, protects kidney function, and reduces proteinuria — simultaneously. Zero approved drugs target it. The commercial field is wide open, particularly in CKD.
Zero competitors in CKD.
02
AP001 — The Analog
Native apelin-13 degrades in minutes in the bloodstream. Dr. Lim's lab engineered AP001: a modified analog with extended half-life, designed for subcutaneous delivery. Eleven iterations of structural refinement. One lead candidate. Ready for IND-enabling studies.
11 iterations. Ready for IND.
03
The CPET Endpoint
Clinical trials in CKD have failed on endpoints that don't capture what matters to patients. Dr. Lim's CPET platform measures VO2 peak, cardiac output, and gas exchange during exercise — scientifically rigorous and deeply meaningful to the patient in the chair.
The only CKD CPET lab in America.
Support the Foundation

Your gift is what stands between a discovery and a medicine.

Gifts to VeraCura Health Foundation are fully tax-deductible. Every dollar funds Dr. Lim's research, patient access programs, and the scientific infrastructure that makes new medicines possible.

Direct Cash Gift
Any amount · Fully deductible
Unrestricted gifts fund laboratory operations, research personnel, equipment, and patient education. Every amount matters. Make a check payable to VeraCura Health Foundation, or contact us to give online.
Donor Advised Fund
Grant from your DAF
Recommend a grant from your DAF — through Fidelity Charitable, Schwab, National Christian Foundation, Vanguard, or any community foundation. We are registered to receive DAF grants. Often the most tax-efficient giving vehicle for major donors.
Appreciated Assets
Avoid capital gains
Gifts of publicly traded securities or real estate may allow you to deduct full fair market value while avoiding capital gains tax entirely. Contact us for transfer instructions and consult your financial advisor.
The Team

Builders, fundraisers, and scientists — working on the same problem.

KL
Dr. Kenneth Lim
Scientific Founder
Harvard and Cambridge trained physician-scientist and nephrologist. FAHA, FASN, FRCP. Active NIH NHLBI R01 PI at IU School of Medicine. Attending Physician, IU Health. Founder of the nation's only CKD-focused CPET laboratory. 15+ years of cardiorenal research.
RK
Richard Klopp
Founding Executive Director
Founder, Avenir Consulting (1994). 30-year track record: 28 startups, 14 turnarounds, 19 boards. Faculty, IU Lilly Family School of Philanthropy. Former CEO, Water for Good. Leads the Foundation's fundraising, governance, and mission.
TC
Todd Colpron
Founding Development Officer
Capital formation, business development, and philanthropic fundraising. Leads the Foundation's major gift campaign, donor relationships, and strategic development partnerships.

The science is ready.
The lab is open.
Are you in?

Thirty-seven million patients are waiting. Dr. Lim's lab is their best shot. Your gift closes the gap between what's possible and what's real.